Exploring the Rapid Growth of Wearables in the Pharma & Biotech Market by 2031

The Future of Wearables in Pharma and Biotech Market

The wearables sector within the pharmaceutical and biotechnology industries is on a significant trajectory, with projections estimating remarkable growth from approximately USD 3.98 billion in 2026 to an impressive USD 9.97 billion by 2031. This evolution showcases a compound annual growth rate (CAGR) of 20.2%, shedding light on the mounting enthusiasm for integrating advanced technology into healthcare practices.

Overview of Market Dynamics

According to MarketsandMarkets reports, the upward trend can be attributed to several compelling factors. Firstly, the continuous glucose monitor (CGM) segment represented a substantial 31.3% of the market in 2025, underscoring the demand for more direct patient engagement in chronic disease management. Moreover, pharmaceutical and biotech companies accounted for a significant 53.5% of the wearables market share that same year, indicating a commitment from these sectors to enhance patient outcomes.

In terms of geographical distribution, North America emerged as a leader, claiming 42.3% of the global market. The region’s high adoption rate of connected health technologies, coupled with extensive integration of patient-generated data, reflects a conducive environment for growth.

The Role of Technology in Clinical Trials

As the healthcare landscape evolves, the integration of wearables within clinical research has proven beneficial. The rise of decentralized and hybrid trials, endorsed by regulatory bodies such as the FDA, has borne witness to this growth. For instance, a study published by PLOS Digital Health reveals that 85% of trials assessing wearables involve monitoring chronic disease patients, with a particular focus on neurodegenerative diseases, while 15% aim to diagnose cardiovascular conditions.

Notably, despite only 8% of these studies being randomized trials, 67% demonstrated a measurable clinical impact, illustrating the potential of wearables for improving clinical trial efficiencies. These devices not only facilitate the collection of real-time data but also engage patients more effectively than traditional methods.

Segment Growth and Future Trends

The diabetes segment, in particular, is set to experience rapid growth, driven by steep increases in the global diabetic population. Current estimations, based on updates from the International Diabetes Federation, anticipate that the number of adults with diabetes could rise from 589 million to over 850 million by 2050. In the U.S. alone, over 38 million individuals currently manage diabetes, signaling a substantial market for monitoring solutions.

Furthermore, clinical trials remain a focal point, exhibiting the largest market share in 2025 within the wearable space. This segment's growth is propelled by the necessity for efficient, patient-centric designs that produce high data content, essential for informed decision-making in drug development processes.

North America at the Forefront

The leading position of North America can be attributed to its high adoption rate of digital health technologies and strong institutional support. Funding from entities such as the National Institutes of Health and reimbursement frameworks for remote patient monitoring bolster the integration and utilization of wearable technologies in this region. Research indicates that 44.5% of respondents utilize wearables, with rates notably higher among younger, urban, and affluent demographics. This consumer behavior provides a continuous input of real-world health data pertinent to pharma and biotech companies.

Notable Companies Driving Innovation

Key players in this burgeoning wearable market include industry giants such as BD, Abbott, Apple Inc., and Medtronic, among others. These companies are leading the charge in innovation, enhancing the user experience and efficacy of wearables within healthcare settings.

In conclusion, the projections for the wearables market in pharma and biotech paint a promising picture for the future. As technology continues to blend seamlessly with healthcare, the potential for improved patient outcomes and streamlined clinical processes becomes increasingly achievable. The next few years are poised to witness significant advancements driven by an unyielding focus on innovation and efficiency, establishing a new paradigm in patient care and clinical research.